시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 고정용량 복합제 흡입기 시장 보고서(2025년)
Fixed-Dose Combination Inhalers Global Market Report 2025
상품코드 : 1810895
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

고정용량 복합제 흡입기 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 CAGR 10.1%로 207억 6,000만 달러로 성장합니다. 예측 기간 중의 성장은 천식 및 만성폐쇄성폐질환의 유병률 증가, 호흡기 치료에서 간편한 치료 접근법에 대한 수요 증가, 흡입요법의 장점에 대한 인식 증가, 노인 인구 증가, 병용요법 채택 확대 등에 기인하는 것으로 보입니다. 이 기간 중 예상되는 주요 동향으로는 흡입기 장치의 기술 발전, 스마트 흡입기 기술의 통합, 건식 분말 흡입기(DPI) 제형의 발전, 센서 및 연결 기능의 통합, 프로펠런트 프리 흡입기 시스템의 혁신 등이 있습니다.

천식 유병률 증가는 향후 수년간 복합 흡입기 시장의 성장을 가속할 것으로 예측됩니다. 천식은 기도의 만성 염증 상태로, 기도의 협착과 점액 생성 증가로 인해 호흡곤란을 유발하는 질환입니다. 천식 환자 수가 증가하고 있는 것은 대기오염 증가로 인해 호흡기에 자극과 염증을 일으켜 호흡기 질환을 유발하는 것이 주요 원인입니다. 복합제(FDC) 흡입기는 일반적으로 기도의 염증을 억제하는 코르티코스테로이드와 기도 근육을 이완시키는 기관지확장제의 두 가지 약물을 하나의 장치로 투여하여 천식 관리를 돕고 증상 조절과 치료 순응도를 모두 개선합니다. 예를 들어 2023년 11월 호주의 비영리단체인 National Asthma Council은 2022년 한 해 동안 호주의 천식 관련 사망자 수를 467명(여성 299명, 남성 168명)으로 보고했습니다. 그 결과, 천식 유병률 증가는 고정용량 복합제 흡입기 시장 확대에 기여하고 있습니다.

복합제 병용 흡입기 시장의 주요 기업은 천식, 만성폐쇄성폐질환(COPD) 등 만성 호흡기 질환의 치료 성과 향상, 환자 순응도 강화, 관리 효율화를 위해 3제 혼합 건조분말 흡입기 등 혁신적 개발에 주력하고 있습니다. 고정용량 3제 병용 건식 분말 흡입기는 천식 및 COPD를 치료하기 위해 세 가지 약물을 고정 용량으로 투여하는 단일 장치입니다. 예를 들어 2023년 11월 인도 제약회사 루핀 리미티드(Lupin Limited)는 COPD 치료용 정량적 3제 병용 흡입기 Vilfuro G를 출시했습니다. 이 제품은 폐 기능을 향상시키고 숨가쁨, 기침 등의 증상을 완화하고 악화를 예방합니다. 1일 1회 투여와 3중 작용기전으로 중등도에서 중증의 COPD 환자에게 효과적이고 장기적인 조절을 제공합니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

Fixed-dose combination (FDC) inhalers are devices designed to deliver two or more medications-such as corticosteroids and bronchodilators-at fixed doses within a single inhaler for the treatment of respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD). By simplifying therapy and enhancing the synergistic effects of drugs, they help improve patient adherence and clinical outcomes.

The primary types of fixed-dose combination inhalers include corticosteroid and bronchodilator combination inhalers, long-acting beta agonist and inhaled corticosteroid combination inhalers, triple combination inhalers, and others. Corticosteroid and bronchodilator combination inhalers pair an anti-inflammatory corticosteroid with a bronchodilator to reduce inflammation in the airways and relax airway muscles. These inhalers are widely used for treating various conditions, including asthma and chronic obstructive pulmonary disease (COPD), and are available through several distribution channels such as retail pharmacies, hospital pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The fixed-dose combination inhalers market research report is one of a series of new reports from The Business Research Company that provides fixed-dose combination inhalers market statistics, including the fixed-dose combination inhalers industry's global market size, regional shares, competitors with the fixed-dose combination inhalers market share, detailed fixed-dose combination inhalers market segments, market trends and opportunities, and any further data you may need to thrive in the fixed-dose combination inhalers market. This fixed-dose combination inhalers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fixed-dose combination inhalers market size has grown rapidly in recent years. It will grow from $12.80 billion in 2024 to $14.12 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth during the historic period can be attributed to increased healthcare spending, a growing preference among patients for portable and user-friendly inhalers, a rise in regulatory approvals for innovative combination inhalers, expanded use of digital health platforms, and a heightened emphasis on personalized respiratory care.

The fixed-dose combination inhalers market size is expected to see rapid growth in the next few years. It will grow to $20.76 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to the increasing prevalence of asthma and chronic obstructive pulmonary disease, rising demand for simplified treatment approaches in respiratory care, greater awareness of the advantages of inhalation therapy, a growing elderly population, and the expanding adoption of combination therapy. Key trends expected during this period include technological advancements in inhaler devices, the integration of smart inhaler technology, progress in dry powder inhaler (DPI) formulations, incorporation of sensors and connectivity features, and innovations in propellant-free inhaler systems.

The rising incidence of asthma is expected to drive the growth of the fixed-dose combination inhalers market in the coming years. Asthma is a chronic inflammatory condition of the airways, leading to breathing difficulties due to airway narrowing and increased mucus production. The growing number of asthma cases is largely attributed to increasing air pollution, which irritates and inflames the airways, making individuals more prone to respiratory issues. Fixed-dose combination (FDC) inhalers support asthma management by delivering two medications-typically a corticosteroid to reduce airway inflammation and a bronchodilator to relax the airway muscles-within a single device, improving both symptom control and treatment adherence. For example, in November 2023, the National Asthma Council, an Australian non-profit organization, reported 467 asthma-related deaths in Australia during 2022-comprising 299 females and 168 males-an increase from 355 deaths recorded in 2021. Consequently, the growing prevalence of asthma is contributing to the expansion of the fixed-dose combination inhalers market.

Leading companies in the fixed-dose combination inhaler market are focusing on innovative developments, such as fixed-dose triple combination dry powder inhalers, to improve treatment outcomes, enhance patient compliance, and streamline the management of chronic respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD). A fixed-dose triple combination dry powder inhaler is a single device that delivers three medications in a fixed dose to treat asthma and COPD. For instance, in November 2023, Lupin Limited, a pharmaceutical company based in India, introduced Vilfuro G, a fixed-dose triple combination inhaler for the treatment of COPD. This product enhances lung function, alleviates symptoms like shortness of breath and coughing, and helps prevent exacerbations. Its once-daily dosing and triple-action mechanism provide effective, long-term control for individuals with moderate to severe COPD.

In April 2024, Launch Therapeutics Inc., a clinical development company based in the United States, partnered with Teva Pharmaceutical Industries Ltd. to accelerate the development and clinical validation of Teva's dual-action asthma rescue inhaler (ICS-SABA/TEV-'248). This inhaler may become the first fixed-dose combination inhaler to include both an inhaled corticosteroid and a short-acting beta-agonist for use in adult and pediatric asthma patients. Teva Pharmaceutical Industries Ltd. is a pharmaceutical company headquartered in Israel that produces fixed-dose combination inhalers.

Major players in the fixed-dose combination inhalers market are Novartis AG., AstraZeneca plc., GlaxoSmithKline plc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Chiesi Farmaceutici S.p.A., Dr. Reddy's Laboratories, Cipla Ltd., Hikma Pharmaceuticals plc., Amneal Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Orion Corporation, Alembic Pharmaceuticals Ltd., Sava Healthcare Limited, Micro Labs Limited, Indoco Remedies Ltd., Vectura Group plc., and Pulmatrix Inc.

North America was the largest region in the fixed-dose combination inhalers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fixed-dose combination (FDC) inhalers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fixed-dose combination (FDC) inhalers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fixed-dose combination (FDC) inhalers market consists of sales of products including seretide, symbicort, breo ellipta, trelegy ellipta, and duova. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fixed-Dose Combination Inhalers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fixed-dose combination inhalers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for fixed-dose combination inhalers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The fixed-dose combination inhalers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Fixed-Dose Combination Inhalers Market Characteristics

3. Fixed-Dose Combination Inhalers Market Trends And Strategies

4. Fixed-Dose Combination Inhalers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Fixed-Dose Combination Inhalers Growth Analysis And Strategic Analysis Framework

6. Fixed-Dose Combination Inhalers Market Segmentation

7. Fixed-Dose Combination Inhalers Market Regional And Country Analysis

8. Asia-Pacific Fixed-Dose Combination Inhalers Market

9. China Fixed-Dose Combination Inhalers Market

10. India Fixed-Dose Combination Inhalers Market

11. Japan Fixed-Dose Combination Inhalers Market

12. Australia Fixed-Dose Combination Inhalers Market

13. Indonesia Fixed-Dose Combination Inhalers Market

14. South Korea Fixed-Dose Combination Inhalers Market

15. Western Europe Fixed-Dose Combination Inhalers Market

16. UK Fixed-Dose Combination Inhalers Market

17. Germany Fixed-Dose Combination Inhalers Market

18. France Fixed-Dose Combination Inhalers Market

19. Italy Fixed-Dose Combination Inhalers Market

20. Spain Fixed-Dose Combination Inhalers Market

21. Eastern Europe Fixed-Dose Combination Inhalers Market

22. Russia Fixed-Dose Combination Inhalers Market

23. North America Fixed-Dose Combination Inhalers Market

24. USA Fixed-Dose Combination Inhalers Market

25. Canada Fixed-Dose Combination Inhalers Market

26. South America Fixed-Dose Combination Inhalers Market

27. Brazil Fixed-Dose Combination Inhalers Market

28. Middle East Fixed-Dose Combination Inhalers Market

29. Africa Fixed-Dose Combination Inhalers Market

30. Fixed-Dose Combination Inhalers Market Competitive Landscape And Company Profiles

31. Fixed-Dose Combination Inhalers Market Other Major And Innovative Companies

32. Global Fixed-Dose Combination Inhalers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fixed-Dose Combination Inhalers Market

34. Recent Developments In The Fixed-Dose Combination Inhalers Market

35. Fixed-Dose Combination Inhalers Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기